Shiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Over-expression of Wilm’s Tumor Gene 1 (WT1) in Iranian Patients with Acute Myeloblastic Leukemia182190ENHosseinAsgarianDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
IranMahdiShabaniDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
Iranmsshabani@yahoo.comParvanehVosooghClinic of Hematology, Ali-Asghar Hospital, Faculty of Medicine, Iran University of Medical
Sciences, Tehran, IranRamazan AliSharifianClinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine,
Tehran University of Medical Sciences, Tehran, IranSoheilaGharagozlouDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
IranJalalKhoshnoodiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
IranTaherehShahrestaniDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
IranMahinKordmahinClinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine,
Tehran University of Medical Sciences, Tehran, IranAbdolfattahSarrafnejadDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
IranMahmoodJeddi TehraniImmune and Gene Therapy Lab, Cancer Center
Karolinska, Karolinska Hospital, Stockholm, Sweden | Monoclonal Antibody Research Center, Avesina
Research Institute, Tehran, IranHodjatallahRabbaniImmune and Gene Therapy Lab, Cancer Center
Karolinska, Karolinska Hospital, Stockholm, Sweden | Monoclonal Antibody Research Center, Avesina
Research Institute, Tehran, IranFazelShokriDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
Iran | Monoclonal Antibody Research Center, Avesina
Research Institute, Tehran, Iran | National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iranfshokri@sina.tums.ac.irBackground: The Wilm’s tumor gene 1 (WT1) encodes a zinc finger transcription factor that is inactivated in a subset of Wilm’s tumors. It plays a crucial role in growth, proliferation and development of some embryonic and adult organs. WT1 is expressed as a tumor associated antigen (TAA) in various types of solid and hematopoietic malignancies and can be employed as a useful marker for targeted immunotherapy and monitoring of minimal residual disease (MRD). Objective: To investigate the profile of WT1 gene expression in Iranian patients with acute myeloblastic leukemia. Methods: RT-PCR method was used to determine the WT1 gene expression in bone marrow (BM) and/or peripheral blood (PB) samples from 11 patients with AML and PB samples of 36 normal subjects. Isolated cells from all patients were immunophenotyped by flow cytometry. Results: The leukemic cells from 10 patients (91%) were found moderately or strongly positive for WT1 expression whereas only 3 out of 36 normal subjects expressed WT1 at very low levels. A highly significant correlation was observed for WT1 expression between paired BM and PB samples of the AML patients. Conclusion: Our results indicate that WT1 is expressed in the majority of Iranian AML patients and may be employed for screening and monitoring of minimal residual disease in these patients.Wilm’s Tumor Gene 1,Acute Myeloblastic Leukemia,Tumorassociated,Antigen,RT-PCRhttp://iji.sums.ac.ir/article_16916.htmlhttp://iji.sums.ac.ir/article_16916_20d63b55ce3e64a5f798285aa473545a.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Serum Level of HER-2 Extracellular Domain in Iranian Patients with Breast Cancer: A Follow-up Study191200ENMehrnooshDoroudchiDepartment of Immunology | Shiraz Institute for Cancer Research (ICR)mdoroud@sums.ac.irAbdolrasoulTaleiShiraz Institute for Cancer Research (ICR) | Department of Surgery,
Shiraz University of Medical Sciences, Shiraz, IranHelmoutModjtahediDivision of Oncology, Postgraduate Medical
School, University of Surrey, UK, andAlamtajSamsami DehaghaniDepartment of OB & GYN, Shiraz University of Medical
Sciences, Shiraz, Iransamsamia@sums.ac.irAbdol MohammadPezeshkiShiraz Institute for Cancer Research (ICR)HilaryThomasDivision of Oncology, Postgraduate Medical
School, University of Surrey, UK, andAbbasGhaderiDepartment of Immunology | Shiraz Institute for Cancer Research (ICR)ghaderia@sums.ac.irBackground: A soluble form of HER-2/neu extracellular domain (sHER-2) is reported to be released in the sera of metastatic breast cancer patients. Objective: To measure the level of sHER-2 in sera of 115 breast cancer patients. Methods: Serial samples of 27 patients with metastasis, 18 non-metastatic patients, 15 patients in stage 0/I and 14 patients with accompanying benign breast disease were also included in this study. Results: No significant difference was observed between sHER- 2 level in the pre-operative sera of breast cancer patients and that of healthy individuals. Only 8 out of 27 patients whom later developed metastasis showed elevated levels of sHER-2 in their first serum sample. However, a trend of increase in the level of sHER-2 was observed in 14 (51.8%) of 27 metastatic sera before clinical diagnosis of the metastasis. A significant association between sHER-2 positive status and vascular invasion of the tumor was observed (P = 0.02). In addition, significant correlation of sHER-2 level with CEA (highest r = 0.74) and CA 15.3 (highest r = 0.74) tumor marker levels in the serial sera were observed. The mean time from sHER-2 positivity to tumor metastasis was calculated to be 98 days (range = 29-174). Conclusion: Our results indicate that a relatively high percentage of Iranian patients with breast cancer show an elevated level of sHER-2 in their sera before clinical diagnosis of the tumor metastasis. Therefore, measuring the level of this oncoprotein, not only helps physicians in monitoring the patients during HERCEPTINTM therapy, but also can be helpful in choosing more aggressive treatments at the early satges of tumor metastasis.Breast Cancer,HER-2,Iranian,serumhttp://iji.sums.ac.ir/article_16917.htmlhttp://iji.sums.ac.ir/article_16917_48200f4acabb9501900b477229decbac.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Deficient Expression of Bruton's Tyrosine Kinase in Monocytes from X-Linked Agammaglobulinemia as Evaluated by a Flow Cytometric Analysis and its Clinical Application to Carrier Detection201207ENAsgharAghamohammadiDepartment of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of
Medical Sciences, Tehran, Iranaghamohammadi@sina.tums.ac.irAli AkbarAmirzargarDepartment of Immunogenetics, Tehran University of Medical
Sciences, Tehran, Iranamirzargar_ali@yahoo.comNimaParvanehDepartment of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of
Medical Sciences, Tehran, IranPaulMarjousefDepartment of Immunogenetics, Tehran University of Medical
Sciences, Tehran, IranMostafaMoinDepartment of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of
Medical Sciences, Tehran, IranAbdolhassanFarhoudiDepartment of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of
Medical Sciences, Tehran, IranMehdiYeganehDepartment of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of
Medical Sciences, Tehran, IranToshioMiyawakiDepartment of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical
University, Toyama, JapanBackground: The B-cell defect in X-linked agammaglobulinemia (XLA) is caused by mutations in the gene for Bruton's tyrosine kinase (BTK). BTK mutations result in deficient expression of BTK protein in peripheral blood monocytes. Methods: Using the anti-BTK monoclonal antibody (48-2H), a flow cytometric analysis of intra cytoplasmic BTK protein expression in monocytes was performed to identify Iranian patients with XLA phenotype. To examine the possible identification of XLA patients and female carriers by this assay, we studied 13 XLA families. Results: The flow cytometric assay showed deficient expression of the BTK protein in 12 (92%) families. One patient exhibited a normal level of BTK expression. The cellular mosaicism of BTK expression in monocytes from obligate carriers was clearly shown in 9 of 12 (75%) families. Conclusion: The results suggested that most XLA patients have deficient expression of the BTK protein; therefore we conclude that deficient expression of BTK protein can be evaluated by a flow cytometric assay.Bruton's Tyrosine Kinase(BTK),X-linked Agammaglobulinemia,(XLA),BTK Expressionhttp://iji.sums.ac.ir/article_16918.htmlhttp://iji.sums.ac.ir/article_16918_39235fa21edf436511c3ff1889fd7f79.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Effects of Recombinant Human Erythropoietin Pretreatment on Anti-HLA Antibody Titer: A Preclinical Experience in Rats208212ENAkbarVahdatiBiology Department, Faculty of Sciences, Isfahan University, IsfahanMinooAdibImmunology Department, Faculty
of Medicine, Isfahan University of Medical Sciences, Isfahan,adib@med.mui.ac.irShirinKashfiBiology Department, Faculty of Sciences, Isfahan University, Isfahansh_kashfi@yahoo.comTajiAfroozBiology Department, Faculty of Sciences, Isfahan University, IsfahanEdnaAbkarImmunogenetics Lab., Ali Asghar
hospital, Isfahan, IranBackground: Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. New studies show the effects of EPO on immune system. Objective: In this study, the effects of pretreatment with recombinant human erythropoietin (rHuEPO) on the anti-human leukocyte antibody (anti-HLA) titer were determined. Methods: Three groups of rats were sensitized with human lymphocytes. Two of the groups were given 20 or 100 IU/Kg rHuEPO after two sensitizations with human lymphocytes. Control group did not receive rHuEPO. Microlymphocytotoxicity method was used to detect anti-HLA antibodies. Results: Treatment with rHuEPO caused a significant decline in anti-HLA antibody titer compared to control group. Also, pretreatment with rHuEPO suppressed antibody response after repeated antigenic stimulation. Conclusion: Such results could be due to the effects of rHuEPO on the number or the activity of the B and the T cells. Moreover, the dose of rHuEPO and the length of treatment might affect anti-HLA antibody titer.Anti-HLA Antibody Titer,rHuEPO,Lymphocyteshttp://iji.sums.ac.ir/article_16920.htmlhttp://iji.sums.ac.ir/article_16920_4a6a9de07844f6a235c708cd5691ee59.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201The Assessment of NK Cytotoxicity and CD56+/CD16+ Phenotype by Flowcytometry in PBL Isolated from Women with Recurrent Spontaneous Abortion213219ENAlirezaAndalibImmunology department, Isfahan Medical School, Isfahan University of Medical Sciences (IUMS),
Isfahan, Iranandalib@med.mui.ac.irAbbasRezaieImmunology department, Isfahan Medical School, Isfahan University of Medical Sciences (IUMS),
Isfahan, IranFarzadOreizyImmunology department, Isfahan Medical School, Isfahan University of Medical Sciences (IUMS),
Isfahan, IranSimaBaluchiImmunology department, Isfahan Medical School, Isfahan University of Medical Sciences (IUMS),
Isfahan, IranBackground: Human peripheral blood NK cells constitutively express CD56 and CD16 antigens. Peripheral blood NK cells seem to be strongly related with decidual NK cells, and may reflect the decidual NK cell functional status. There are varied reports concerning the relationship between NK cell cytotoxicity in women with recurrent spontaneous abortion. Objective: To study NK activity in women with history of RSA by using a non-radioactive cytotoxicity assay. Methods: Peripheral blood lymphocytes from RSA and healthy multiparous women were obtained. Lymphocytes were isolated and mixed with K562 NK-sensitive cell line. A non-radioactive method for NK cell cytotoxicity assessment was utilized. Dead K562 cell populations were detected by FACS Calibur flow cytometry, and the data obtained was analysed on cell-Quest software. The proportion of CD16+ /CD56+ cells was then calculated. Results: The proportion of NK cells were 9.21% ± 3.06 and 13.48% ± 4.09 in healthy women and RSA, respectively. The percentage of cytotoxicity was determined to be 19.3% ± 3.9 in healthy group and 27.1% ± 6.5 in RSA group with an effector:target ratio of 50:1. The data shows an increase in PBLs potential for in vitro cytotoxicity assay in RSA individuals. The analyses indicate that there is a weak positive correlation between NK cytotoxicity potential and the percentage of NK cells in PBL population. Conclusion: The present study demonstrates that the percentage of CD56+ /CD16+ cells increases in individuals with recurrent spontaneous abortion. We conclude that NK cytotoxicity as well as NK number is partially involved in RSA.Flow-cytometry,/CD16+,CD56+,Blood Lymphocytes,NK Cytotoxicity,abortion,Peripheralhttp://iji.sums.ac.ir/article_16921.htmlhttp://iji.sums.ac.ir/article_16921_d41f7c1c56581c5d38bf704c8a2e06b0.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Evaluation of the Serum Levels of Immunoglobulin and Complement Factors in b-thalassemia Major Patients in Southern Iran220225ENAhmadAminHematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranSusanJalaliHematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranRezaAminDepartment of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranSoheilaAale-yasinDepartment of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranNimaJamalianHematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranMehranKarimiHematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Irankarimim@sums.ac.irBackground: Beta-thalassemia major is one of the major health problems in our country. Many studies have confirmed the fact that, these patients have an increased susceptibility to bacterial infections. Objective: In this study, we have assessed the humoral immune system in 68 thalassemic patients by measuring their serum concentration of Immunoglobulin G (IgG), IgM, IgA, C3 and C4 in order to find out a responsible immune defect. Methods: Sixty eight b-thalassemia major patients were enrolled randomly from referrals to Dastgheib clinic of thalassemia. The same number of case controls with matched age and sex were selected from healthy people without any history of recent or recurrent infections. Serum IgG, IgM, IgA, C3 and C4 levels were assessed using Single Radial Immunodiffusion (SRID). Results: Serum levels of IgG, IgM & IgA were significantly higher (PThalassemia Major,IgG,IgA,IgM,C3 and C4http://iji.sums.ac.ir/article_16922.htmlhttp://iji.sums.ac.ir/article_16922_b069c05a642c97bb6c7ffa7b5f75228f.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Polymorphism in the First Intron of Interferon-Gamma Gene (+874T→A) in Iranian Patients with Brucellosis226231ENManoochehrRasouliProf. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iranrasouliman@yahoo.comSiminKianyProf. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IranAbdolvahhabAlborziProf. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IranBackground: Brucella is a gram-negative bacterium, causing acute and chronic infection in humans and animals. Cell-mediated immunity is the main protective immune response against Brucella spp. Activation of macrophages by IFN-γ and generation of reactive oxygen intermediates and nitric oxide are the main immunologic mechanisms responsible for control of Brucella infection. Objective: To investigate the correlation between IFN-γ gene polymorphism and brucellosis. Methods: 195 patients with brucellosis, 186 healthy patients' family members and 82 healthy farmers who kept infected animals and consumed their contaminated dairy products were selected to take part in the study. IFN-γ genotyping at position +874 (T→A) was carried out by allele specific polymerase chain reaction (AS-PCR) method. Results: The frequency of AT and TT genotypes significantly increased in farmers compared to patients with brucellosis (P=0.03) while there was no significant difference in genotype distribution between patients and their healthy family members. Conclusion: IFN-γ (+874) AA genotype is probably a genetic factor that contributes to the susceptibility of the individuals to brucellosis.Brucella,Interferon Gamma,Genetic Polymorphismhttp://iji.sums.ac.ir/article_16923.htmlhttp://iji.sums.ac.ir/article_16923_c2a6d670dbaf5c6099948dee4e450eca.pdfShiraz Institute for Cancer ResearchIranian Journal of Immunology1735-13831735-367X2420051201Ethics of Tissue and Stem Cell Transplantation232240ENBehrouzNikbinImmunogenetics lab, Department of Immunologydnik@ams.ac.irMandanaMohyeddin BonabHematology-Oncology Research Center, Shariati
Hospital, Tehran University of Medical Sciencesmohyeddin@sina.tums.ac.irFatemehTalebianImmunogenetics lab, Department of ImmunologyTissue and cell transplantation are regarded as a popular procedure in clinical sciences, prospecting a new horizon for several incurable diseases. Along with its usefulness, many ethical concerns accompany this development. The ethical issue of organ transplant is unique to the source used which includes: living related, living unrelated, cadaveric, and xenotransplant. Obtaining organs has a separate set of ethical concerns which are discussed under two headings, namely salvage and donation. Then there is the issue of organ marketing and the ethical, social, and economical issues it encompasses. All these are active areas of debate, and we have touched upon them by turn. This century has brought a new aspect of transplantation into the light, stem cell transplantation. Here we present some work done recently on mesenchymal stem cells and their outcome. These cells are now being employed in the therapy of some incurable ailments. It seems this kind of transplantation, although possessing its own range of issues, could prove to be the way of the future.ethics,Transplantation,Stem Cellhttp://iji.sums.ac.ir/article_16924.htmlhttp://iji.sums.ac.ir/article_16924_7ba9ffda643e7cbc500de4d580400af4.pdf